IL17A and neoplasm: Several members of interleukins (ILs) such as IL-1, IL-8, IL-12 (Vasudev and Reynolds)6 and, more recently, IL-17 (Chung et al.33) have been implicated in tumor refractoriness to anti-VEGF agents.